A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy

Melanoma Clinical Trial

— TdVax  

Official title:

A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05077137
• Other study ID #: Pro00108367
• Status: Recruiting
• Phase: Phase 1
• Start date: September 7, 2021
• Est. completion date: September 1, 2024

Study information

• Verified date: October 2023
• Source: Duke University
• Contact: Carol Ann Wiggs, BSN
• Phone: 919-684-0281
• Email: carolann.wiggs[@]duke.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and feasibility of administering the Tetanus Diptheria Vaccine (Td) or Polio Boost Immunization (IPOL) to patients with metastatic melanoma who are receiving immune checkpoint inhibitor (IO) therapy per standard of care. Subjects will have the vaccine at cycle 4 of IO therapy and will have research blood and tissue samples collected prior to starting IO therapy, at cycle 4 prior to vaccine administration, and at 12-17 days post vaccine.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: September 1, 2024
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed advanced metastatic melanoma

2. Male or female participants who are at least 18 years of age on the day of signing informed consent

3. Participants must be planned or scheduled by their treating physician to receive PD-1 therapy or PD-1 plus anti CTLA-4 therapy as standard of care

4. Participant (or legally acceptable representative if applicable) provides written informed consent for the trial

5. Participant must have at least 1 lesion that is at least 8 mm in size and is cutaneous, subcutaneous, palpable, or amenable to ultrasound guided core biopsy. The lesion chosen for biopsy can also be a target lesion but does not have to be a target lesion

6. Adequate organ function as defined below. Standard of care labs drawn within 45 days prior to consent may be used for the purposes of determining eligibility

1. ANC >/= 1500/uL

2. platelets >/=100,000/uL

3. Hemoglobin >/= 9.0 g/dL

Exclusion Criteria:

1. Uveal or mucosal melanoma

2. Any women known to be pregnant or breastfeeding

3. Any prior systemic therapy for metastatic melanoma (prior surgery is allowed)

4. Known diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone or equivalent), or any other form of immunosuppressive therapy within 7 days prior to first research biopsy

5. Patients with symptomatic CNS metastases and/or carcinomatous meningitis a) Patients with asymptomatic, stable CNS metastases are allowed provided that they are not on >10mg prednisone daily

6. History of or active (non-infectious) pneumonitis that required steroids

7. Active infection requiring systemic therapy

8. Known history of Human Immunodeficiency Virus (HIV) infection

9. Known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. NOTE: no testing for Hepatitis B or Hepatitis C is required

10. Known history of active TB (Bacillus Tuberculosis)

11. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with subject's participation for the full duration of the study, or make it not in the best interest of the subject to participate, in the opinion of the treating physician

12. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

13. History of allogenic tissue or solid organ transplant

14. History of allergic reaction to IPOL or Td vaccine

15. Receipt of Td vaccine within 30 days prior to starting IO therapy

Related Conditions & MeSH terms

• Melanoma

Intervention

Biological:
• Tetanus Diptheria Vaccine
tetanus and diphtheria toxoids
• Polio Boost Immunization
trivalent inactivated polio vaccine

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects out of the proposed 25 that successfully receive the vaccine after 4 cycles of IO therapy	Evaluable patients are defined as those who receive four cycles of IO therapy and then receive a Td or IPOL vaccine	informed consent through date of vaccine (est apx 4-5 months)
Primary	Safety, as measured by the change in the number and severity of adverse events deemed related to the vaccine or study procedures (blood draw and biopsies)	Adverse events will only include those that are determined to be related to the study vaccine or study procedures (blood draw and biopsies)	Baseline, cycle 4 of IO therapy (apx 12-16 weeks), 12-17 days post vaccine, SOC scan following vaccine (apx 8-12 weeks post vaccine)
Secondary	Preliminary efficacy, as measured by objective response rate	Number of patients that experience tumor response vs. stable disease vs. progression as determined by PI assessment of standard of care scans	up to 36 months